Get started
Author

Phil McKernan

Observed names: Mckernan, P, P McKernan, P. McKernan
OpenAlex ID: A5069633002
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma
2021 · Stephan Braun, Paul McSheehy, et al. · Expert Opinion on Investigational Drugs · 18
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations
2024 · Andrea Necchi, Rodryg Ramlau, et al. · JNCI Cancer Spectrum · 10
Efficacy and Safety of Canakinumab in Patients with Cryopyrin Associated Periodic Syndrome: Results From Meta-Analysis of 5 Studies
2012 · Lachmann, HJ, Kuemmerle-Deschner, JB, et al. · UCL Discovery (University College London) · 5
Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.
2023 · Andrea Necchi, Tilman Todenhöfer, et al. · Journal of Clinical Oncology · 4
Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.
2019 · Juanita Suzanne Lopez, Rebecca Sophie Kristeleit, et al. · Journal of Clinical Oncology · 2
Phase 1/2a study of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.
2018 · Markus Joerger, Ioannis Metaxas, et al. · Journal of Clinical Oncology · 1
Phase 1/2a trial of daily oral BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors.
2017 · Rebecca Sophie Kristeleit, T.R. Jeffry Evans, et al. · Journal of Clinical Oncology · 1
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.
2017 · Alvaro Henrique Ingles Garces, Elizabeth R. Plummer, et al. · Journal of Clinical Oncology · 1
A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01
2026 · Mitesh J. Borad, Michele Droz dit Busset, et al. · Hepatology
Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors.
2018 · Juanita Suzanne Lopez, Elizabeth Ruth Plummer, et al. · Journal of Clinical Oncology
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.
2017 · Markus Joerger, Anastasios Stathis, et al. · Journal of Clinical Oncology
P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized
2013 · A Gautier, P Lowe, et al. · Pediatric Rheumatology
PDF
Enhanced immune activation in adulthood following childhood trauma: A role for toll-like receptors
2010 · P. McKernan, G. Gaszner, et al. · Brain Behavior and Immunity
Works count: 13
Citation count: 42
H-index: 4
I10-index: 2
Year
Topic
Type